<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766037</url>
  </required_header>
  <id_info>
    <org_study_id>P12-001V</org_study_id>
    <nct_id>NCT01766037</nct_id>
  </id_info>
  <brief_title>Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study</brief_title>
  <acronym>PATHWAY</acronym>
  <official_title>Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspire Bariatrics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Mary Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aspire Bariatrics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being performed to find out if a new device, AspireAssist Aspiration
      Therapy System, can help people with obesity to lose weight without causing too many side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Aspiration process works by &quot;correcting&quot; meal portions after eating by removing some of
      the food left in your stomach 20 minutes after your meal, which reduces the number of
      calories absorbed by your body. This is done through a tube placed through the abdomen into
      the stomach with a small valve attached at the surface of your skin. An aspiration system
      will attach to that valve after each major meal of the day and allow you to remove a portion
      of that meal.

      During this study you will also be provided with Lifestyle therapy which includes behavioral
      therapy, diet and physical activity education. This Lifestyle therapy will also be provided
      to the participants who do not receive the AspireAssist so that the two groups can be
      compared and the benefit of aspiration for weight loss can be determined.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Excess Weight Loss (%EWL)</measure>
    <time_frame>52 weeks</time_frame>
    <description>The first effectiveness co-primary endpoint is the mean percent excess weight loss (%EWL) at 52-weeks. The hypothesis for the first primary effectiveness endpoint is that the difference in the mean percent excess weight loss (%EWL) at 52-weeks for the Aspiration Therapy (AT) group and Control group is at least 10%. Percent EWL is defined as absolute weight loss divided by baseline excess weight and multiplied by 100. Excess weight is determined from ideal body weights based on a BMI=25 kg/m2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of Subjects Who Achieve &gt;25% EWL</measure>
    <time_frame>52 weeks</time_frame>
    <description>The second co-primary effectiveness endpoint is that at least 50% of the AT group at 52-weeks achieve &gt; 25% EWL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Total Body Weight Loss</measure>
    <time_frame>52 weeks</time_frame>
    <description>i) Mean percent absolute weight loss in AT compared to Control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With ≥10% Total Body Weight Loss</measure>
    <time_frame>52 weeks</time_frame>
    <description>ii) proportion of subjects who achieve ≥10% absolute weight loss in AT compared to Control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Serum Lipids</measure>
    <time_frame>52 weeks</time_frame>
    <description>iii) mean percent change serum lipids (triglyceride, HDL-cholesterol and LDL-cholesterol concentration) in the AT group compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Blood Pressure</measure>
    <time_frame>52 weeks</time_frame>
    <description>iv) mean percent change in systolic and diastolic blood pressures in the AT group compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score for IWQOL Questionnaire</measure>
    <time_frame>52 weeks</time_frame>
    <description>v) &quot;Impact of Weight on Quality of Life&quot; (IWQOL) questionnaire total score
Total score ranges from a minimum of 0 to a maximum of 100. Based on the algorithm developed by Crosby, et.al., patients' IWQOLLite total scores are considered to have shown meaningful improvement from baseline to one year if they increased between 7 and 12 points, depending upon baseline severity in comparison to the normative mean. Normative means for the IWQOL-Lite have been derived from a sample of 534 non-obese individuals who were not enrolled in any weight loss treatment program [238 women and 296 men with BMI's between 18.5 and 29.9]. The data presented is the mean change in total score. The AT group demonstrated a mean improvement (increase) in score of 16.3 points, the Control group a mean improvement (increase) of 11.7 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hemoglobin A1C</measure>
    <time_frame>52 weeks</time_frame>
    <description>vi) change in mean hemoglobin A1C (only subjects with T2 diabetes at baseline). Hemoglobin A1C is measured as DCCT%. The change in mean DCCT% from Baseline to Week 52 is reported for this secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>52 weeks</time_frame>
    <description>vii) percent procedural success (defined as successful endoscopic placement of the A-Tube) in all subjects undergoing endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medication for Hypertension</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of medications taken by subjects for hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medications for Dyslipidemia</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of medications taken by subjects for dyslipidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medications for Type 2 Diabetes</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of medications taken by subjects for Type 2 Diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Subjects on Hypertension Medication</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of subjects on Hypertension medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Subjects on Dyslipidemia Medications</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of subjects on Dyslipidemia medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Subjects on Diabetes Medication</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in the number of subjects on Diabetes medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>52 weeks</time_frame>
    <description>The incidence of procedure-related, device-related, and therapy-related serious adverse events. Also, the development of adverse eating behaviors will be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Aspiration Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspiration Therapy and Lifestyle Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle Therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aspiration Therapy (AspireAssist)</intervention_name>
    <description>Use of the AspireAssist device in aspiration therapy</description>
    <arm_group_label>Aspiration Therapy</arm_group_label>
    <other_name>AspireAssist Aspiration Therapy System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Therapy</intervention_name>
    <description>Lifestyle therapy is a behavioral, diet and physical activity education program</description>
    <arm_group_label>Aspiration Therapy</arm_group_label>
    <arm_group_label>Lifestyle Therapy</arm_group_label>
    <other_name>Lifestyle Behavioral Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Measured BMI of 35.0-55.0 kg/m2 at time of screening.

          2. 21- 65 years of age (inclusive) at time of screening.

          3. Failed attempt for a duration equal to 3-months at weight loss by alternative
             approaches (e.g. supervised or unsupervised diets, exercise, behavioral modification
             programs).

          4. Stable weight (&lt;3% change in self-reported weight) over the previous 3 months at time
             of screening).

          5. Women of childbearing potential must agree to use at least one form of birth control
             (prescription hormonal contraceptives, diaphragm, IUD, condoms with or without
             spermicide, or voluntary abstinence) from time of study enrollment through study exit.

          6. Willing and able to provide informed consent in English and comply with the protocol.

        Exclusion Criteria:

          1. Previous abdominal surgery that significantly increases the medical risks of
             gastrostomy tube placement

          2. Esophageal stricture, pseudo-obstruction, severe gastroparesis or gastric outlet
             obstruction, inflammatory bowel disease

          3. History of refractory gastric ulcers

          4. Ulcers, bleeding lesions, or tumors discovered during endoscopic examination.

          5. History of radiation therapy to the chest or abdomen

          6. Uncontrolled hypertension (blood pressure &gt;160/100).

          7. Diabetes treated with insulin or sulfonylurea medications

          8. Any change in diabetes medication in previous 3 months

          9. Hemoglobin A1C &gt;9.5%

         10. History or evidence of serious pulmonary or cardiovascular disease, including acute
             coronary syndrome, heart failure requiring medications, or NYHA (New York Heart
             Association) class III or IV heart failure (defined below):

             Class III: patients with marked limitation of activity and who are comfortable only at
             rest Class IV: patients who should be at complete rest, confined to bed or chair and
             who have discomfort with any physical activity

         11. Coagulation disorders (platelets &lt; 100,000, PT &gt; 2 seconds above control or INR &gt; 1.5)

         12. Anemia (Hemoglobin &lt;11.0 g/dL in women and &lt;12.5 g/dL in men)

         13. Liver enzymes (ALT and AST) ≥3.0 times the upper limit of normal

         14. Thyroid Stimulating Hormone (TSH) &gt;1.5 x upper limit of normal at screening.

         15. Osteoporosis (DEXA T-Score ≤ -2.5 standard deviations below normal peak values).

         16. History of fragility fractures (fractures resulting from a fall from a standing height
             or less, or presenting in the absence of obvious trauma)

         17. Pregnant or lactating

         18. Diagnosed Bulimia or diagnosed Binge Eating Disorder (using DSM IV criteria)

         19. Night Eating Syndrome (diagnosed by EDE)

         20. Serum potassium &lt; 3.8 mEq/L

         21. Chronic abdominal pain that would potentially complicate the management of the device

         22. Taking a GLP-1 agonist &lt; 6 months.

         23. Taking prescription or over-the-counter medications for weight loss in the last 3
             months before screening, or planning to participate in a commercial weight loss
             program in the next 24 months.

         24. Taking medication once or more per week that causes weight gain (e.g. atypical
             antipsychotics, monoamine oxidase inhibitors, lithium, selected anticonvulsants,
             tamoxifen, glucocorticoids)

         25. Self- reported history of substance abuse in last 3 years.

         26. Malignancy in the last 5 years (except for non-melanoma skin cancer).

         27. Physical or mental disability, or psychological illness that could interfere with
             compliance with the therapy.

         28. At high risk of having a medical complication from the endoscopic procedure or
             Aspiration Therapy weight loss program for any reason, including poor general health
             or severe organ dysfunction, such as cirrhosis or renal dysfunction (GFR &lt;60
             mL/min/1.73 m2 at screening, calculated by using the Chronic Kidney Disease
             Epidemiology Collaboration (CKD-EPI) equation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Thompson, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept VA San Diego Health Care System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Center for Wellness and Weight Loss Surgery</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Center for Weight and Eating Disorders</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aspirebariatrics.com</url>
    <description>Aspire Bariatrics, Inc. Study Sponsor Website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <results_first_submitted>July 13, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>obese</keyword>
  <keyword>weight loss</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Screened Oct 30, 2012 First Subject Enrolled Nov 13, 2012 Last Subject Enrolled June 13, 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspiration Therapy</title>
          <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
        <group group_id="P2">
          <title>Lifestyle Therapy</title>
          <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved from area</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>medical - unrelated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>nausea / discomfort</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Aspiration Therapy</title>
          <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
        <group group_id="B2">
          <title>Lifestyle Therapy</title>
          <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="10.0"/>
                    <measurement group_id="B2" value="46.8" spread="11.6"/>
                    <measurement group_id="B3" value="43.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.9" spread="21.2"/>
                    <measurement group_id="B2" value="112.8" spread="16.1"/>
                    <measurement group_id="B3" value="115.4" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Excess Weight Loss (%EWL)</title>
        <description>The first effectiveness co-primary endpoint is the mean percent excess weight loss (%EWL) at 52-weeks. The hypothesis for the first primary effectiveness endpoint is that the difference in the mean percent excess weight loss (%EWL) at 52-weeks for the Aspiration Therapy (AT) group and Control group is at least 10%. Percent EWL is defined as absolute weight loss divided by baseline excess weight and multiplied by 100. Excess weight is determined from ideal body weights based on a BMI=25 kg/m2.</description>
        <time_frame>52 weeks</time_frame>
        <population>Modified Intent To Treat (mITT) population defined as all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Excess Weight Loss (%EWL)</title>
          <description>The first effectiveness co-primary endpoint is the mean percent excess weight loss (%EWL) at 52-weeks. The hypothesis for the first primary effectiveness endpoint is that the difference in the mean percent excess weight loss (%EWL) at 52-weeks for the Aspiration Therapy (AT) group and Control group is at least 10%. Percent EWL is defined as absolute weight loss divided by baseline excess weight and multiplied by 100. Excess weight is determined from ideal body weights based on a BMI=25 kg/m2.</description>
          <population>Modified Intent To Treat (mITT) population defined as all enrolled subjects</population>
          <units>Percent Excess Weight Loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="26.7"/>
                    <measurement group_id="O2" value="9.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% of Subjects Who Achieve &gt;25% EWL</title>
        <description>The second co-primary effectiveness endpoint is that at least 50% of the AT group at 52-weeks achieve &gt; 25% EWL.</description>
        <time_frame>52 weeks</time_frame>
        <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>% of Subjects Who Achieve &gt;25% EWL</title>
          <description>The second co-primary effectiveness endpoint is that at least 50% of the AT group at 52-weeks achieve &gt; 25% EWL.</description>
          <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
          <units>Percent of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="49.0" upper_limit="64.5"/>
                    <measurement group_id="O2" value="22.0" lower_limit="15.3" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Total Body Weight Loss</title>
        <description>i) Mean percent absolute weight loss in AT compared to Control group</description>
        <time_frame>52 weeks</time_frame>
        <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Total Body Weight Loss</title>
          <description>i) Mean percent absolute weight loss in AT compared to Control group</description>
          <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
          <units>Percent Total Weight Loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="9.6"/>
                    <measurement group_id="O2" value="3.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With ≥10% Total Body Weight Loss</title>
        <description>ii) proportion of subjects who achieve ≥10% absolute weight loss in AT compared to Control group</description>
        <time_frame>52 weeks</time_frame>
        <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With ≥10% Total Body Weight Loss</title>
          <description>ii) proportion of subjects who achieve ≥10% absolute weight loss in AT compared to Control group</description>
          <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
          <units>Percent of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="50.3" upper_limit="66.6"/>
                    <measurement group_id="O2" value="11.9" lower_limit="5.7" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Serum Lipids</title>
        <description>iii) mean percent change serum lipids (triglyceride, HDL-cholesterol and LDL-cholesterol concentration) in the AT group compared to the control group</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects who completed 52 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Serum Lipids</title>
          <description>iii) mean percent change serum lipids (triglyceride, HDL-cholesterol and LDL-cholesterol concentration) in the AT group compared to the control group</description>
          <population>Subjects who completed 52 weeks</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Density Lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="4.2" upper_limit="12.0"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-3.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" lower_limit="-8.5" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-8.8" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" lower_limit="-17.7" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-15.9" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Blood Pressure</title>
        <description>iv) mean percent change in systolic and diastolic blood pressures in the AT group compared to the control group</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects who completed 52 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Blood Pressure</title>
          <description>iv) mean percent change in systolic and diastolic blood pressures in the AT group compared to the control group</description>
          <population>Subjects who completed 52 weeks</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-4.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-5.9" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-5.2" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-4.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score for IWQOL Questionnaire</title>
        <description>v) &quot;Impact of Weight on Quality of Life&quot; (IWQOL) questionnaire total score
Total score ranges from a minimum of 0 to a maximum of 100. Based on the algorithm developed by Crosby, et.al., patients’ IWQOLLite total scores are considered to have shown meaningful improvement from baseline to one year if they increased between 7 and 12 points, depending upon baseline severity in comparison to the normative mean. Normative means for the IWQOL-Lite have been derived from a sample of 534 non-obese individuals who were not enrolled in any weight loss treatment program [238 women and 296 men with BMI’s between 18.5 and 29.9]. The data presented is the mean change in total score. The AT group demonstrated a mean improvement (increase) in score of 16.3 points, the Control group a mean improvement (increase) of 11.7 points.</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects who completed the Questionnaire at 52 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score for IWQOL Questionnaire</title>
          <description>v) &quot;Impact of Weight on Quality of Life&quot; (IWQOL) questionnaire total score
Total score ranges from a minimum of 0 to a maximum of 100. Based on the algorithm developed by Crosby, et.al., patients’ IWQOLLite total scores are considered to have shown meaningful improvement from baseline to one year if they increased between 7 and 12 points, depending upon baseline severity in comparison to the normative mean. Normative means for the IWQOL-Lite have been derived from a sample of 534 non-obese individuals who were not enrolled in any weight loss treatment program [238 women and 296 men with BMI’s between 18.5 and 29.9]. The data presented is the mean change in total score. The AT group demonstrated a mean improvement (increase) in score of 16.3 points, the Control group a mean improvement (increase) of 11.7 points.</description>
          <population>Subjects who completed the Questionnaire at 52 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.5" upper_limit="20.1"/>
                    <measurement group_id="O2" value="11.7" lower_limit="5.5" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hemoglobin A1C</title>
        <description>vi) change in mean hemoglobin A1C (only subjects with T2 diabetes at baseline). Hemoglobin A1C is measured as DCCT%. The change in mean DCCT% from Baseline to Week 52 is reported for this secondary endpoint.</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects with Type 2 Diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin A1C</title>
          <description>vi) change in mean hemoglobin A1C (only subjects with T2 diabetes at baseline). Hemoglobin A1C is measured as DCCT%. The change in mean DCCT% from Baseline to Week 52 is reported for this secondary endpoint.</description>
          <population>Subjects with Type 2 Diabetes</population>
          <units>DCCT% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-3.7" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-0.37" lower_limit="-0.77" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>vii) percent procedural success (defined as successful endoscopic placement of the A-Tube) in all subjects undergoing endoscopy</description>
        <time_frame>52 weeks</time_frame>
        <population>All A-Tube placement attempts</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>vii) percent procedural success (defined as successful endoscopic placement of the A-Tube) in all subjects undergoing endoscopy</description>
          <population>All A-Tube placement attempts</population>
          <units>Percent Procedural Success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medication for Hypertension</title>
        <description>Percent change in the number of medications taken by subjects for hypertension</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated with medications for hypertension</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medication for Hypertension</title>
          <description>Percent change in the number of medications taken by subjects for hypertension</description>
          <population>Subjects being treated with medications for hypertension</population>
          <units>Percent Change in Medications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.5"/>
                    <measurement group_id="O2" value="-9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medications for Dyslipidemia</title>
        <description>Percent change in the number of medications taken by subjects for dyslipidemia</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated for high cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medications for Dyslipidemia</title>
          <description>Percent change in the number of medications taken by subjects for dyslipidemia</description>
          <population>Subjects being treated for high cholesterol</population>
          <units>Percent Change in Medications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1"/>
                    <measurement group_id="O2" value="-7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medications for Type 2 Diabetes</title>
        <description>Percent change in the number of medications taken by subjects for Type 2 Diabetes</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated for Type 2 Diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medications for Type 2 Diabetes</title>
          <description>Percent change in the number of medications taken by subjects for Type 2 Diabetes</description>
          <population>Subjects being treated for Type 2 Diabetes</population>
          <units>Percent Change in Medications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.0"/>
                    <measurement group_id="O2" value="-14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Subjects on Hypertension Medication</title>
        <description>Percent change in the number of subjects on Hypertension medication</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated for hypertension</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Subjects on Hypertension Medication</title>
          <description>Percent change in the number of subjects on Hypertension medication</description>
          <population>Subjects being treated for hypertension</population>
          <units>% Change in Subjects on Medication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.1"/>
                    <measurement group_id="O2" value="-10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Subjects on Dyslipidemia Medications</title>
        <description>Percent change in the number of subjects on Dyslipidemia medications</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated for high cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Subjects on Dyslipidemia Medications</title>
          <description>Percent change in the number of subjects on Dyslipidemia medications</description>
          <population>Subjects being treated for high cholesterol</population>
          <units>% Change in Subjects on Medication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1"/>
                    <measurement group_id="O2" value="-8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Subjects on Diabetes Medication</title>
        <description>Percent change in the number of subjects on Diabetes medication</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects being treated for Type II Diabetes</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Subjects on Diabetes Medication</title>
          <description>Percent change in the number of subjects on Diabetes medication</description>
          <population>Subjects being treated for Type II Diabetes</population>
          <units>% Change in Subjects on Medication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3"/>
                    <measurement group_id="O2" value="-16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Outcomes</title>
        <description>The incidence of procedure-related, device-related, and therapy-related serious adverse events. Also, the development of adverse eating behaviors will be assessed.</description>
        <time_frame>52 weeks</time_frame>
        <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration Therapy</title>
            <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
          <group group_id="O2">
            <title>Lifestyle Therapy</title>
            <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcomes</title>
          <description>The incidence of procedure-related, device-related, and therapy-related serious adverse events. Also, the development of adverse eating behaviors will be assessed.</description>
          <population>Modified Intent To Treat (mITT) population of all enrolled subjects</population>
          <units>Percent of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosed Eating Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspiration Therapy</title>
          <description>Aspiration Therapy and Lifestyle Therapy
Aspiration Therapy (AspireAssist): Use of the AspireAssist device in aspiration therapy
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
        <group group_id="E2">
          <title>Lifestyle Therapy</title>
          <description>Lifestyle Therapy only
Lifestyle Therapy: Lifestyle therapy is a behavioral, diet and physical activity education program</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Abdominal pain post endoscopic A-Tube placement procedure</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Prepyloric Ulceration</sub_title>
                <description>Non-bleeding pre-pyloric ulceration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <description>Peritonitis (mild pneumo-peritoneum without abscess) post endoscopic A-Tube placement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>A-Tube Replacement</sub_title>
                <description>A-Tube replaced, Site documented as SAE because endoscopy was performed to replace the tube.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain (post procedure)</sub_title>
                <description>Abdominal pain occurring within 4 weeks of the A-Tube endoscopic placement</description>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea / Vomiting</sub_title>
                <description>Nausea and vomiting generally the result of sedation and post procedure pain medication</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <description>Intermittent abdominal discomfort</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal Pain (after 4 weeks)</sub_title>
                <description>Abdominal pain onset more than 4 weeks after A-Tube placement</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Change in Bowel Habits</sub_title>
                <description>Dyspepsia, Constipation, Diarrhea</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peristomal Infection</sub_title>
                <description>Peristomal bacterial infection / possible infection</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Granulation Tissue</sub_title>
                <description>Granulation tissue at the stoma site is a normal healing process but can cause discomfort if not treated.</description>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peristomal Discharge</sub_title>
                <description>Peristomal bleeding, discharge, inflammation, irritation</description>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Regulatory &amp; Quality</name_or_title>
      <organization>Aspire Bariatrics, Inc.</organization>
      <phone>484-200-1031</phone>
      <email>monica.ferrante@aspirebariatrics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

